Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Non-cash Items (2017 - 2025)

Soleno Therapeutics (SLNO) has disclosed Non-cash Items for 5 consecutive years, with $47.4 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $47.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $47.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $47.4 million for FY2025, N/A changed from the prior year.
  • Non-cash Items for Q4 2025 was $47.4 million at Soleno Therapeutics, down from $113.6 million in the prior quarter.
  • The five-year high for Non-cash Items was $113.6 million in Q3 2025, with the low at $47.4 million in Q4 2025.